Investors & Media
Dedicated to delivering long-term investment value.
Featured News: CSL and uniQure Win 2023 Prix Galien USA Award
At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
-
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
Stock Information
Updated stock ticker information for uniQure
- NASDAQ:
- Price:
- Change:
- Volume:
(Updated every 15 minutes)
SEC Filings
Security and exchange commission filings for uniQure, including quarterly and annual reports
Learn MoreUpcoming Webcasts
No webcasts scheduled. Check back soon.
Webcast Archive
-
Regulatory Update for AMT-130
View Webcast
8:30 a.m. ET -
Stifel 2024 Healthcare Conference
View Webcast
1:50 p.m. ET - 2:20 p.m. ET -
Guggenheim Healthcare Innovation Conference
View Webcast
3:30 p.m. ET-3:55 p.m. ET
Investor Presentations
-
July 2024 Huntington's Disease Program Update AMT-130 – Webcast Presentation
View Presentation -
Virtual Research & Development Event – Nov. 29 event focused on preclinical gene therapy candidate for refractory temporal lobe epilepsy (rTLE) AMT-260 and uniQure AAV manufacturing advancements
View Presentation -
Gene Therapy Information
View Presentation